Vismodegib for treating basal cell carcinoma - guidance (TA489)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
22 November 2017

Abstract

Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: November 2020